ZOLTAN KISS CONSULTING

A Family Company

Zoltan Kiss Consulting (ZKC) is a start-up family-owned biotechnological company which has developed a human placenta derived protein (ZKCPr1) to effectively reduce excess visceral (abdominal) fat in obese diabetic mice, without side effects, with the promise that it will have similar major effects in obese and non-obese humans with “belly fat” that presently available drugs, including the GLP-1 and amylin based ones, can provide only with moderate efficacy.

Health risks that may be associated with excess visceral fat as suggested by observational human studies

• Chronic low-grade inflammation
• Insulin resistance, Hyperinsulinemia, Type 2 Diabetes
• High LDL-cholesterol and triglycerides
• General obesity
• Reduces muscle proteins, Weaker Muscles, Less mobility
• Cardiovascular diseases, Kidney diseases, Many cancers
• Stroke
• Pancreatitis
• Reduced life span